Supernus Pharmaceuticals SUPN Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's operating lease right-of-use assets in other assets?
- Supernus Pharmaceuticals (SUPN) reported operating lease right-of-use assets in other assets of $26.4M in Q1 2026.
- How has Supernus Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Supernus Pharmaceuticals's operating lease right-of-use assets in other assets increased by 16.2% year-over-year, from $22.72M to $26.4M.
- What is the long-term trend for Supernus Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 5.7% compound annual growth rate (CAGR), from $20.23M to $26.71M.